NCT05565950View on ClinicalTrials.gov

AI-09 In Subjects With Glabellar Lines, GL-101

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 3, 2022

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

AI-09

Botulinum toxin, Type A, intramuscular injection, administered once at baseline

BIOLOGICAL

Vehicle

Vehicle Formulation

Trial Locations (2)

33137

Eirion Research Site, Miami

33432

Eirion Research Site, Boca Raton

Sponsors
All Listed Sponsors
lead

Eirion Therapeutics Inc.

INDUSTRY